August 14: Esperance Pharmaceuticals Names Prominent Chinese Researcher and Clinician as Scientific Advisor
Poster Presentation: American Association of Cancer Research (AACR) Poster #0405
“EP-100 sensitizes BRCA wild-type ovarian cancer cells to PARP inhibitor”
2017
April 10: Esperance Pharmaceuticals Names Noted Cancer Researcher Mark Pegram MD as Scientific Advisor
2016
March 30: Houston Biotech Esperance Eyes $40M Raise to Fund Cancer Drug Push
2015
April 4: Esperance moves offices to Houston Texas
August 24: Esperance Announces Strategic Alliance with MD Anderson Cancer Center
June 1: Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting
Poster Presentation: American Society of Clinical Oncology (ASCO) #5528
“EP-100 Paclitaxel Overcomes Taxane Resistance in Patients with Recurrent LHRH Receptor Expressing Ovarian Cancer”
2014
2013
Poster Presentation: American Association of Cancer Research (AACR) #978
“Synergistic Activity of EP-100 and Chemotherapies in Cancer Cell Lines”
2012
May 17: Esperance Pharmaceuticals Initiates Phase 2 Clinical Trial of its Novel Membrane-disrupting Agent, EP-100, in Patients with Advanced Ovarian Cancer Esperance
Poster Presentation: American Association of Cancer Research (AACR) #2829
“Activity of EP-100 in Non-Hodgkin’s Lymphoma — Synergy in Combination”
Poster Presentation: American Association of Cancer Research (AACR) #3517
“EP-100 Synergizes with Paclitaxel in Ovarian, Breast and Prostate Cancer Cell Lines”
2011
August 8: Esperance Pharmaceuticals Closes Series B Financing
June 1: Esperance Pharmaceuticals Completes $7.5 Million Series B Financing
Poster Presentation: American Association of Cancer Research #204
“Pre-treatment with FSH Enhances the Ability of a LHRH-Lytic Peptide Conjugate (EP-100) to Target and Destroy Human Pancreatic Cancer Cells”
2010
2009
Poster Presentation: American Association of Cancer Research (AACR) #4666
“Targeted Oncolytic Peptide for Treatment of Ovarian Cancers”
2008
April 24: First Louisiana Biotech Company Focused on Cancer Announces Opening
2006
October 31: Esperance Pharmaceuticals Closes $9 Million Series A Funding